150 related articles for article (PubMed ID: 35343648)
21. Palliative radiotherapy: a one-week course in advanced head and neck cancer - quality of life outcomes.
Prakash S; Chakrabarti D; Kumar R; Agrawal MM; Verma M; Singh S; Gupta S; Srivastava K; Gupta R; Bhatt MLB
BMJ Support Palliat Care; 2022 Apr; ():. PubMed ID: 35428653
[TBL] [Abstract][Full Text] [Related]
22. Racial disparity in oncologic and quality-of-life outcomes in patients with locally advanced head and neck squamous cell carcinomas enrolled in a randomized phase 2 trial.
Guerriero MK; Redman MW; Baker KK; Martins RG; Eaton K; Chow LQ; Santana-Davila R; Baik C; Goulart BH; Lee S; Rodriguez CP
Cancer; 2018 Jul; 124(13):2841-2849. PubMed ID: 29669181
[TBL] [Abstract][Full Text] [Related]
23. Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94).
Ghadjar P; Simcock M; Studer G; Allal AS; Ozsahin M; Bernier J; Töpfer M; Zimmermann F; Betz M; Glanzmann C; Aebersold DM;
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):524-31. PubMed ID: 21300466
[TBL] [Abstract][Full Text] [Related]
24. Comparing high-dose cisplatin with cisplatin-based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC).
Furqan M; Snyders TP; Saqlain MU; Mott SL; Laux D; Snow A; Anderson CM; Watkins JM; Clamon GH
Cancer Med; 2019 Jun; 8(6):2730-2739. PubMed ID: 30968604
[TBL] [Abstract][Full Text] [Related]
25. Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab.
Milowsky MI; O'Donnell PH; Hoimes CJ; Petrylak DP; Flaig TW; Moon HH; Friedlander TW; Mar N; McKay RR; Srinivas S; Gravis G; Ramamurthy C; Bupathi M; Bracarda S; Wright P; Hepp Z; Carret AS; Yu Y; Dillon R; Kataria R; Beaumont JL; Purnajo I; Rosenberg JE
J Clin Oncol; 2024 Apr; 42(12):1403-1414. PubMed ID: 38215355
[TBL] [Abstract][Full Text] [Related]
26. Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH).
Tao Y; Aupérin A; Sun X; Sire C; Martin L; Coutte A; Lafond C; Miroir J; Liem X; Rolland F; Even C; Nguyen F; Saada E; Maillard A; Colin-Batailhou N; Thariat J; Guigay J; Bourhis J
Eur J Cancer; 2020 Dec; 141():21-29. PubMed ID: 33125944
[TBL] [Abstract][Full Text] [Related]
27. Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02).
Lee JY; Sun JM; Oh DR; Lim SH; Goo J; Lee SH; Kim SB; Park KU; Kim HK; Hong DS; Kim JS; Kim SG; Yi SY; Yun HJ; Hyun MS; Kim HJ; Jung SH; Park K; Ahn YC; Ahn MJ
Radiother Oncol; 2016 Feb; 118(2):244-50. PubMed ID: 26705681
[TBL] [Abstract][Full Text] [Related]
28. Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer.
Hitt R; Mesía R; Lozano A; Iglesias Docampo L; Grau JJ; Taberna M; Rubió-Casadevall J; Martínez-Trufero J; Morillo EDB; García Girón C; Vázquez Estévez S; Cirauqui B; Cruz-Hernández JJ
Oral Oncol; 2022 Nov; 134():106087. PubMed ID: 36126605
[TBL] [Abstract][Full Text] [Related]
29. Phase II study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer.
Guntinas-Lichius O; Appenrodt S; Veelken F; Krug B
Laryngoscope; 2006 Apr; 116(4):613-8. PubMed ID: 16585868
[TBL] [Abstract][Full Text] [Related]
30. Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.
Szturz P; Wouters K; Kiyota N; Tahara M; Prabhash K; Noronha V; Castro A; Licitra L; Adelstein D; Vermorken JB
Oncologist; 2017 Sep; 22(9):1056-1066. PubMed ID: 28533474
[TBL] [Abstract][Full Text] [Related]
31. Quality of life, HPV-status and phase angle predict survival in head and neck cancer patients under (chemo)radiotherapy undergoing nutritional intervention: Results from the prospective randomized HEADNUT-trial.
Kutz LM; Abel J; Schweizer D; Tribius S; Krüll A; Petersen C; Löser A
Radiother Oncol; 2022 Jan; 166():145-153. PubMed ID: 34838889
[TBL] [Abstract][Full Text] [Related]
32. Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin.
van der Vorst MJDL; Neefjes ECW; Toffoli EC; Oosterling-Jansen JEW; Vergeer MR; Leemans CR; Kooistra MP; Voortman J; Verheul HMW
BMC Cancer; 2019 Nov; 19(1):1066. PubMed ID: 31703649
[TBL] [Abstract][Full Text] [Related]
33. Clinical benefits of concurrent capecitabine and cisplatin versus concurrent cisplatin and 5-flurouracil in locally advanced squamous cell head and neck cancer.
Gupta S; Khan H; Barik S; Negi MP
Drug Discov Ther; 2013 Feb; 7(1):36-42. PubMed ID: 23524942
[TBL] [Abstract][Full Text] [Related]
34. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
[TBL] [Abstract][Full Text] [Related]
35. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR
Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242
[TBL] [Abstract][Full Text] [Related]
36. Randomized Clinical Trial on Reduction of Radiotherapy Dose to the Elective Neck in Head and Neck Squamous Cell Carcinoma: Results on the Quality of Life.
Deschuymer S; Nevens D; Duprez F; Daisne JF; Voordeckers M; De Neve W; Nuyts S
Qual Life Res; 2021 Jan; 30(1):117-127. PubMed ID: 32920767
[TBL] [Abstract][Full Text] [Related]
37. First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale.
Gebbia V; Lorusso V; Galetta D; Caruso M M; Palomba G; Riccardi F; Borsellino N; Carrozza F; Leo S; Ferraù F; Cinieri S; Mancuso G; Mancarella S; Colucci G
Lung Cancer; 2010 Aug; 69(2):218-24. PubMed ID: 19910076
[TBL] [Abstract][Full Text] [Related]
38. Changing quality of life in patients with advanced head and neck cancer after primary radiotherapy or chemoradiation.
Fang FM; Tsai WL; Chien CY; Chiu HC; Wang CJ; Chen HC; Hsiung CY
Oncology; 2005; 68(4-6):405-13. PubMed ID: 16020970
[TBL] [Abstract][Full Text] [Related]
39. Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer.
Kataoka T; Kiyota N; Shimada T; Funakoshi Y; Chayahara N; Toyoda M; Fujiwara Y; Nibu K; Komori T; Sasaki R; Mukohara T; Minami H
Auris Nasus Larynx; 2016 Dec; 43(6):677-84. PubMed ID: 26992271
[TBL] [Abstract][Full Text] [Related]
40. Phase 1 trial of adavosertib (AZD1775) in combination with concurrent radiation and cisplatin for intermediate-risk and high-risk head and neck squamous cell carcinoma.
Chera BS; Sheth SH; Patel SA; Goldin D; Douglas KE; Green RL; Shen CJ; Gupta GP; Moore DT; Grilley Olson JE; Weiss JM
Cancer; 2021 Dec; 127(23):4447-4454. PubMed ID: 34379792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
